Ignite Creation Date:
2024-06-16 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06457074
Status:
RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-04
Brief Title:
Finerenone for Patients With Primary Aldosteronism FAIRY
Sponsor:
Qifu Li
Organization:
Chongqing Medical University
Study Overview
Official Title:
Finerenone for Patients With Primary Aldosteronism FAIRY A Multicenter Randomized Clinical Trial
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Using spironolactone as the control to assess the efficacy and safety of finerenone in patients with primary aldosteronismPA
Detailed Description:
This is a multicenter randomized study designed to evaluate efficacy and safety of finerenone in patients with PA PA patients are randomly divided into two groups and treated with finerenone or spironolactone for 12 weeks Spironolactone will be used as the control while outcome will be assessed after 12-week treatment Both drugs will be started at 20mg per day Dose will be adjusted every four weeks to achieve the targeted blood pressure
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None